Author: Pietzsch, Hans-Jürgen ; Baumann, Michael ; Krause, Mechthild ; Sihver, Wiebke ; Schreiner, Lena ; Hering, Sandra ; Bergmann, Ralf ; Koi, Lydia ; Dietrich, Antje ; Freudenberg, Robert ; Steinbach, Jörg ; Andreeff, Michael ; Löck, Steffen ; Schubert, Maik ; Kotzerke, Jörg

BACKGROUND AND PURPOSESystemic molecular radiotherapy utilizes internal irradiation by radionuclide-labeled tumor-targeting agents with the potential to destroy (micro-)metastases. However, doses that are applicable in solid tumors do not reach the levels nessecary for tumor control. Thus, the combination of molecular and external radiotherapy is a promising treatment strategy, as enhanced tumor doses can be delivered with and without minor overlapping toxicities. Here, we combined a ⁹⁰Y-labeled anti-EGFR antibody (Cetuximab) with clinically relevant fractionated radiotherapy in a preclinical trial using head and neck squamous cell carcinoma xenograft tumors.MATERIALS AND METHODSTo model ⁹⁰Y-Cetuximab uptake for treatment schedule optimization, FaDu-bearing mice were injected with near-infrared-labeled-Cetuximab at different time points during radiotherapy with differing doses. Cetuximab uptake was longitudinally followed by in vivo-optical imaging. Tumor control probability experiments with fractionated radiotherapy (30 fx, 6 weeks, 8 dose groups/ arm) in combination with ⁹⁰Y-Cetuximab were performed to test the curative potential.RESULTSImaging of near-infrared-labeled-Cetuximab uptake revealed that low to moderate external beam doses can enhance antibody uptake. Using the optimized schedule, combination of molecular and external radiotherapy using ⁹⁰Y-Cetuximab at a dose that did not result in permanent tumor inactivation in previous experiments, led to substantially increased tumor control compared to radiotherapy alone.CONCLUSIONOur results indicate that combination of radiolabeled therapeutics with clinically relevant fractionated radiotherapy has a remarkable potential to improve curative treatment outcome. Application of some radiation dose prior to injection may improve drug uptake and enable patient stratification and treatment personalization via a corresponding PET-tracer during therapy.

01 Apr 1978·Annals of the Rheumatic DiseasesQ1 · MEDICINE

Intra-articular yttrium 90 in rabbits. Comparison of behaviour of various radiocolloids in rabbits and in man.

Q1 · MEDICINE

Article

Author: Gumpel, J. M.

Comparative studies of the retention of various yttrium 90 radiocolloids and of noncolloidal yttrium 90 chloride were performed in rabbits with arthritis induced in one knee. Two colloids, the citrate and resin forms, showed a statistically significant difference in retention between inflamed and normal knees, isotope being retained better in the normal knee. Marked differences were found in the handling of the various yttrium preparations in rabbits compared with previously reported results in man. These differences suggest that the rabbit with induced arthritis is not a suitable model in which to test retention of different radiocolloids before use in man.

100 Deals associated with Anti-EGFR monoclonal antibody-Y-90

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioma	Phase 1	CU	CIMYM Biosciences, Inc.	-
Glioma	Phase 1	IT	-	-
Glioma	Phase 1	-	Gilead Sciences, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Austin 04888 (ESMO_ASIA2018)	Not Applicable	Uveal Melanoma Consolidation	10	Intrahepatic Yttrium-90 microsphere radioembolisation + Intravenous cisplatin	dlaxadbnjn(hymfnckiaw) = iqniucmcav zgztgcngtx (zbikbbwvrd ) View more	Positive	25 Nov 2018
ASCO2009	Phase 2	Advanced Head and Neck Carcinoma	92	h-R3 monoclonal antibody + chemoradiation therapy	(zbifdyejjn) = jflnocdkse pbtuagnykj (ygafsmixhg ) View more	-	20 May 2009
ASCO2009	Phase 2	Advanced Head and Neck Carcinoma	92	chemoradiation therapy	(kbgeexwvas) = zxzivkeqcx snfvwmlqhx (ypmildfvtl ) View more	-	20 May 2009
AACR2009	Not Applicable	Advanced Head and Neck Carcinoma	92	h-R3 monoclonal antibody	ijpqecrobf(zbtutpaniy) = vjsbojsszt oqvfjbvmxk (kgibtsdjpm )	-	01 May 2009
AACR2009	Not Applicable	Advanced Head and Neck Carcinoma	92	chemo-radiation therapy	(viwtxvihjm) = nxhzmvbjxp ugbxibsmso (iaoixhbuwf ) View more	-	01 May 2009
ASCO2008	Not Applicable	Neuroendocrine Tumors	454	Yttrium-90 (Y-90)- and/or lutetium-177 (Lu-177) DOTA-TATE (Lu-TATE)	(scjisuxygk) = gxafurejfn cmjkcdhgki (sbaihumvjm ) View more	-	20 May 2008
ASCO2004	Phase 1	High grade glioma	5	h-R3 MAb labeled with 188-Re	(qbceajgcid) = dwnflwsmot vjmbebuzyh (pyauuwfuhl )	Positive	15 Jul 2004

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Anti-EGFR monoclonal antibody-Y-90

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation